Table 3.
Exophthalmos and eyelid retraction before and after treatment with tocilizumab.
| Variable | No. of Eyes | Pre-Treatment Mean mm (range) |
Post-Treatment Mean mm (range) |
Reduction mm (%) 1 |
p-Value 2 |
|---|---|---|---|---|---|
| Exophthalmos | |||||
| ≤20 mm | 40 | 18.4 (15–20) | 17.2 (13–20) | 1.2 (6.5) | <0.001 |
| 21–22 mm | 18 | 21.6 (21–22) | 19.2 (18–21) | 2.4 (11.1) | <0.001 |
| 23–24 mm | 28 | 23.5 (23–24) | 20.8 (18–24) | 2.7 (11.5) | <0.001 |
| ≥25 mm | 21 | 26.5 (25–29) | 22.7 (18–27) | 3.8 (14.3) | <0.001 |
| Eyelid retraction | |||||
| Upper 3 | 88 | −2.5 (−6 to 0) | −0.2 (−3 to +2) | 2.3 (92.0) | <0.001 |
| Lower 4 | 46 | −1.7 (−3 to −1) | −0.7 (−3 to +2) | 1.0 (58.8) | <0.001 |
1 Reduction in absolute value and percentage with respect to the pre-treatment value. 2 Mean values are shown to facilitate interpretation, while p-values were calculated with the Wilcoxon test (which compares sample medians from both groups). 3 Eyes with a pre-treatment value of >0 mm were excluded from the analysis. 4 Eyes with a pre-treatment value of >−1 mm were excluded from the analysis.